On a therapeutic level, the pan-HER TKI, afatinib, has demonstrated clinical activity in NRG1 rearranged lung cancers with fusions including SDC4-NRG1, SLC3A2-NRG1 and CD74-NRG1. This evidence concerns the gene NRG1 and lung cancer.